Call 855-808-4530 or email GroupSales@alm.com to receive your discount on a new subscription.
Genetic technologies have been a presence in United States courtrooms for decades. In 1987, Tommie Lee Andrews became the first person in the United States to be convicted of a crime based on DNA evidence, spurring the first appellate decision on the admissibility of the results of a genetic test. Andrews v. State, 533 So.2d 841 (Fla. Dist. Ct. App. 1988). Two years later, the case of State v. Woodall, 385 S.E.2d 253 (W. Va. 1989), brought the issue of DNA evidence to a state’s highest court, which concluded that the reliability of genetic testing was generally accepted in the scientific community.
*May exclude premium content
By Steven P. Benenson
In the past several years, plaintiffs’ firms have threatened or brought class actions against different companies under New Jersey’s Truth-in-Consumer Contract Warranty and Notice Act (TCCWNA). Here's what you need to know.
By Mitch Warnock
When you take a catastrophic injury case involving paralysis, it is important to have a thorough understanding of the problems and pitfalls. In this article, the author explores, from personal experience, the different types of future expenses the client can expect to incur.
By Shannon E. McClure and Whitney Mayer
The FDA’s recent approval of 23andMe’s direct-to-consumer genetic test to identify genes associated with 10 common diseases and disorders could result in a widespread expansion of patients armed with individualized health information. This expansion of genetic information in the hands of consumers potentially impacts regulatory and litigation issues for pharmaceutical companies.
Discussion of major rulings out of Texas and California.